aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
5.99
+0.20 (3.45%)
At close: Jul 18, 2025, 4:00 PM
6.13
+0.14 (2.34%)
After-hours: Jul 18, 2025, 6:27 PM EDT

aTyr Pharma Statistics

Total Valuation

aTyr Pharma has a market cap or net worth of $533.14 million. The enterprise value is $477.34 million.

Market Cap533.14M
Enterprise Value 477.34M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025, after market close.

Earnings Date Aug 12, 2025
Ex-Dividend Date n/a

Share Statistics

aTyr Pharma has 89.00 million shares outstanding. The number of shares has increased by 33.04% in one year.

Current Share Class 89.00M
Shares Outstanding 89.00M
Shares Change (YoY) +33.04%
Shares Change (QoQ) +4.55%
Owned by Insiders (%) 2.27%
Owned by Institutions (%) 70.56%
Float 86.98M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 6.87
P/TBV Ratio 7.20
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 7.79, with a Debt / Equity ratio of 0.17.

Current Ratio 7.79
Quick Ratio 7.24
Debt / Equity 0.17
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -79.70% and return on invested capital (ROIC) is -45.00%.

Return on Equity (ROE) -79.70%
Return on Assets (ROA) -39.82%
Return on Invested Capital (ROIC) -45.00%
Return on Capital Employed (ROCE) -77.46%
Revenue Per Employee n/a
Profits Per Employee -$975,569
Employee Count65
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +254.44% in the last 52 weeks. The beta is 0.90, so aTyr Pharma's price volatility has been lower than the market average.

Beta (5Y) 0.90
52-Week Price Change +254.44%
50-Day Moving Average 4.73
200-Day Moving Average 3.65
Relative Strength Index (RSI) 67.96
Average Volume (20 Days) 4,155,259

Short Selling Information

The latest short interest is 18.46 million, so 20.75% of the outstanding shares have been sold short.

Short Interest 18.46M
Short Previous Month 13.64M
Short % of Shares Out 20.75%
Short % of Float 21.23%
Short Ratio (days to cover) 6.12

Income Statement

Revenue n/a
Gross Profit -52.82M
Operating Income -67.05M
Pretax Income -53.93M
Net Income -63.41M
EBITDA -66.35M
EBIT -67.05M
Earnings Per Share (EPS) -$0.80
Full Income Statement

Balance Sheet

The company has $76.35 million in cash and $12.99 million in debt, giving a net cash position of $63.36 million or $0.71 per share.

Cash & Cash Equivalents 76.35M
Total Debt 12.99M
Net Cash 63.36M
Net Cash Per Share $0.71
Equity (Book Value) 74.86M
Book Value Per Share 0.84
Working Capital 72.59M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$62.16 million and capital expenditures -$48,000, giving a free cash flow of -$62.21 million.

Operating Cash Flow -62.16M
Capital Expenditures -48,000
Free Cash Flow -62.21M
FCF Per Share -$0.70
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

aTyr Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -33.04%
Shareholder Yield -33.04%
Earnings Yield -11.73%
FCF Yield -11.50%

Analyst Forecast

The average price target for aTyr Pharma is $20.20, which is 237.23% higher than the current price. The consensus rating is "Strong Buy".

Price Target $20.20
Price Target Difference 237.23%
Analyst Consensus Strong Buy
Analyst Count 6
Revenue Growth Forecast (5Y) 363.01%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on July 1, 2019. It was a reverse split with a ratio of 0.0714285:1.

Last Split Date Jul 1, 2019
Split Type Reverse
Split Ratio 0.0714285:1

Scores

aTyr Pharma has an Altman Z-Score of -3.89 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -3.89
Piotroski F-Score 2